Astellas is pulling out of its $1.6 billion biobucks partnership with CytomX six years after the two companies set out to explore T-cell-engaging bispecifics for the treatment of solid tumors.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Astellas is pulling out of its $1.6 billion biobucks partnership with CytomX six years after the two companies set out to explore T-cell-engaging bispecifics for the treatment of solid tumors.